HC Wainwright Has Bullish Forecast for AUTL Q2 Earnings

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) – Research analysts at HC Wainwright boosted their Q2 2026 earnings per share (EPS) estimates for Autolus Therapeutics in a report issued on Monday, August 3rd. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings per share of ($0.22) for the quarter, up from their previous estimate of ($0.31). HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Autolus Therapeutics’ current full-year earnings is ($0.95) per share. HC Wainwright also issued estimates for Autolus Therapeutics’ Q3 2026 earnings at ($0.21) EPS, Q4 2026 earnings at ($0.19) EPS, FY2026 earnings at ($0.88) EPS, FY2027 earnings at ($0.74) EPS, FY2028 earnings at ($0.83) EPS, FY2029 earnings at ($0.69) EPS and FY2030 earnings at ($0.23) EPS.

Autolus Therapeutics (NASDAQ:AUTL) last announced its earnings results on Friday, May 15th. The company reported ($0.27) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.02. The firm had revenue of $26.22 million for the quarter, compared to analysts’ expectations of $26.27 million. Autolus Therapeutics had a negative net margin of 311.98% and a negative return on equity of 128.59%.

Several other equities research analysts have also commented on AUTL. Jefferies Financial Group raised shares of Autolus Therapeutics to a “strong-buy” rating in a research note on Monday, April 20th. Needham & Company LLC reaffirmed a “buy” rating and set a $10.00 target price on shares of Autolus Therapeutics in a research note on Thursday, April 9th. Wall Street Zen upgraded shares of Autolus Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, June 13th. Finally, Weiss Ratings cut Autolus Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $8.75.

Autolus Therapeutics Price Performance

Shares of Autolus Therapeutics stock opened at $1.95 on Wednesday. The company has a 50-day moving average of $1.58 and a 200 day moving average of $1.53. The firm has a market cap of $519.01 million, a price-to-earnings ratio of -1.79 and a beta of 2.07. Autolus Therapeutics has a 1 year low of $1.18 and a 1 year high of $2.52.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in AUTL. Invesco Ltd. grew its holdings in shares of Autolus Therapeutics by 53.3% during the first quarter. Invesco Ltd. now owns 32,738 shares of the company’s stock valued at $51,000 after buying an additional 11,381 shares during the last quarter. Jane Street Group LLC raised its holdings in Autolus Therapeutics by 809.4% in the 1st quarter. Jane Street Group LLC now owns 102,493 shares of the company’s stock worth $159,000 after acquiring an additional 91,222 shares during the last quarter. Geode Capital Management LLC raised its holdings in Autolus Therapeutics by 90.5% in the 2nd quarter. Geode Capital Management LLC now owns 164,314 shares of the company’s stock worth $375,000 after acquiring an additional 78,058 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in Autolus Therapeutics by 41.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 38,419 shares of the company’s stock valued at $88,000 after acquiring an additional 11,289 shares in the last quarter. Finally, Bank of America Corp DE boosted its stake in Autolus Therapeutics by 2,891.7% during the 2nd quarter. Bank of America Corp DE now owns 975,135 shares of the company’s stock valued at $2,223,000 after purchasing an additional 942,540 shares during the last quarter. Institutional investors own 72.83% of the company’s stock.

Key Stories Impacting Autolus Therapeutics

Here are the key news stories impacting Autolus Therapeutics this week:

• Positive Sentiment: Autolus reported preliminary second-quarter 2026 AUCATZYL net product revenue of approximately $45 million and raised its full-year 2026 sales guidance to $140 million-$150 million from $120 million-$135 million. The new range is also above the roughly $128.1 million consensus estimate, signaling better-than-expected commercial momentum. Autolus preliminary second-quarter revenue and credit facility announcement
• Positive Sentiment: The company also reported an approximately 35% year-to-date gross margin and secured a five-year, interest-only credit facility of up to $250 million, with $75 million funded at closing. The financing improves near-term liquidity to support manufacturing and commercialization, though it adds debt obligations.
• Positive Sentiment: HC Wainwright reiterated its Buy rating and $10 price target. The analyst raised estimated losses for the second and third quarters of 2026 to $0.22 and $0.21 per share, respectively, from $0.31 and $0.27, and lifted the full-year 2026 estimate to a $0.88 loss from $1.08. HC Wainwright reiterates Buy rating for Autolus Therapeutics
• Neutral Sentiment: Autolus will release complete second-quarter 2026 results and operational updates before the U.S. market opens on August 11. Investors will look for confirmation of the preliminary revenue, gross margin, AUCATZYL demand and cash outlook. Autolus second-quarter 2026 earnings release date
• Negative Sentiment: Despite the improved 2026 outlook, HC Wainwright reduced its EPS forecasts for 2027 through 2030, including cuts to a $0.74 loss for 2027, an $0.83 loss for 2028 and a $0.69 loss for 2029. These revisions suggest profitability may take longer to achieve and could limit the stock’s upside.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.